(HealthDay News) — For patients with non-muscle invasive bladder cancer, undergoing the purified protein derivative skin test prior to bacillus Calmette-Guérin therapy may have therapeutic impact, according to a study published in the June issue of The Journal of Urology.
Naoya Niwa, MD, from the Keio University School of Medicine in Tokyo, and colleagues treated 498 patients with non-muscle invasive bladder cancer with adjuvant bacillus Calmette-Guérin; 320 of the patients underwent the purified protein derivative skin test 1 to 2 weeks before therapy.
The researchers found that the mean ± standard deviation 5-year recurrence-free survival rate was 66.6 ± 2.8% and 59.1 ± 4.1% for patients who did and did not undergo the purified protein derivative skin test, respectively (P=0.048). There were no significant differences between the groups in progression-free survival. Significant independent associations with tumor recurrence were seen for a history of recurrence, multiple tumors, the bacillus Calmette-Guérin Connaught strain, 7 or more bacillus Calmette-Guérin instillations, and undergoing the purified protein derivative skin test. Overall, 24.1 and 15.2% of patients who did and did not undergo the test, respectively, had major bacillus Calmette-Guérin-related side effects (P=0.02).
“Combination therapy with bacillus Calmette-Guérin using the purified protein derivative skin test may improve the oncologic outcomes of that therapy,” the authors write.
Niwa N, Kikuchi E, Matsumoto K, Kosaka T, Mizuno R, and Oya R. Purified Protein Derivative Skin test prior to bacillus Calmette-Guérin Therapy May have Therapeutic Impact in Patients With Nonmuscle Invasive Bladder Cancer. J Urol. DOI:10.1016/j.juro.2017.12.057